Home
Scholarly Works
69P The diabetes drug canagliflozin sensitizes...
Conference

69P The diabetes drug canagliflozin sensitizes non-small cell lung cancer (NSCLC) to radiotherapy and chemotherapy

Authors

Tsakiridis T; Villani L; Broadfield L; Marcinko K; Tsakiridis E; Ellis P; Muti P; Steinberg G

Volume

13

Publisher

Elsevier

Publication Date

April 1, 2018

DOI

10.1016/s1556-0864(18)30345-9

Conference proceedings

Journal of Thoracic Oncology

Issue

4

ISSN

1556-0864

Contact the Experts team